Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock?
07:42am, Friday, 30'th Jan 2026
Regenxbio (RGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
07:01pm, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to con
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
06:06pm, Thursday, 29'th Jan 2026
(NASDAQ: RGNX) NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Regenxbio Inc. (NASDAQ: RGNX) regarding potential gaps between information provided to investors and under
RGNX ALERT: Levi & Korsinsky Investigates REGENXBIO Inc. for Possible Securities Fraud Violations
11:41am, Thursday, 29'th Jan 2026
New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning po
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
02:16pm, Wednesday, 28'th Jan 2026
ATLANTA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) complied with federal securities laws. On
FDA Clinical Hold Knocks REGENXBIO Stock
12:31pm, Wednesday, 28'th Jan 2026
REGENXBIO Inc. (NASDAQ: RGNX) shares are tumbling on Wednesday with a session volume of 3.83 million versus an average volume of 684.271 thousand.
US FDA places clinical hold on Regenxbio's gene therapy trials
07:46am, Wednesday, 28'th Jan 2026
Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene therapy programs for rare childhood diseases after a brain tumor was found
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
07:30am, Wednesday, 28'th Jan 2026
ROCKVILLE, Md., Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy
REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away
08:28am, Tuesday, 27'th Jan 2026
Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially transforming it into a commercial-stage gene therapy company. RGX-121 offers a uni
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:25pm, Wednesday, 14'th Jan 2026
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
New Phase I/II RGX-202 functional data demonstrates long-term, durable treatment effect at pivotal dose at 18 months Robust patient enrollment in confirmatory trial continues, expect majority of pat
Assenagon Asset Management S.A. Purchases 132,942 Shares of REGENXBIO Inc. $RGNX
03:16am, Monday, 22'nd Dec 2025
Assenagon Asset Management S.A. increased its position in REGENXBIO Inc. (NASDAQ: RGNX) by 23.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities a
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Brokerages
01:32am, Monday, 22'nd Dec 2025
REGENXBIO Inc. (NASDAQ: RGNX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat Ratings reports. One
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:05am, Thursday, 18'th Dec 2025
ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P.
REGENXBIO to Participate in Upcoming Investor Conference
07:05am, Tuesday, 25'th Nov 2025
ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference F
